CSL is investigating two potential new treatments for sickle cell disease: An injected monoclonal antibody designed to ...

Columnist Oluwatosin Adesoye once feared how sickle cell complications would affect her future, but they ended up opening ...

Casgevy is now approved in the U.S. for children with sickle cell as young as 2, becoming the first gene-editing therapy for this age group.

The U.S. Food and Drug Administration is speeding up its review of an oral medicine for sickle cell disease that may fill a ...

Sickle cell disease (SCD) prognosis varies depending on disease severity and other factors, but the overall life expectancy for the inherited blood disorder has increased notably over recent decades.

An ongoing, early-phase clinical trial of pociredir, an oral small molecule being developed by Fulcrum Therapeutics as a possible treatment for sickle cell disease (SCD), is still recruiting adult ...

A vaso-occlusive crisis (VOC), a hallmark of sickle cell disease (SCD), is an episode of intense pain related to blood vessel blockage and a lack of oxygen supply. In SCD, genetic mutations lead to ...

A Phase 1b clinical trial has exceeded the enrollment target for the group of adults with sickle cell disease (SCD) who will receive the highest dose of Fulcrum Therapeutics‘ experimental oral therapy ...

Marisa Wexler is a senior science writer for Sickle Cell Disease News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of sickle cell topics.

A new, interactive application touted as the first of its kind can help people with sickle cell disease (SCD) learn about and communicate with their care team about their pain attacks. People with ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google For individuals living with sickle cell disease (SCD), daily life ...